BioMarin Pharmaceutical Inc.
BMRN
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPSā¦ read more
Healthcare
Biotechnology
26 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$57.54
Price-0.79%
-$0.46
1Y
Price
Market Cap
$11.049b
Large
Price/Earnings 3y Avg5y Avg
17x
Premium
Premium
Financials Overview
Key metrics over the past few years+37.1%
EBITDA Margin+29.1%
Net Profit Margin+20.4%
Free Cash Flow MarginRevenue
$3.055b
+7.0%
1y CAGR+13.5%
3y CAGR+13.5%
5y CAGREarnings
$657.241m
+54.0%
1y CAGR+75.7%
3y CAGR+137.0%
5y CAGREPS
$3.38
+64.1%
1y CAGR+72.3%
3y CAGR+132.8%
5y CAGRBook Value
$6.027b
$7.456b
Assets$1.429b
Liabilities$603.866m
DebtDebt to Assets
8.1%
0.7x
Debt to EBITDAFree Cash Flow
$691.429m
+45.4%
1y CAGR+294.1%
3y CAGR+201.6%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company